Dr. William Cohn is the chief medical officer for BiVACOR, a medical device company creating the first total artificial heart. Photo via TMC

It's hard to understate the impact Dr. William Cohn has had on cardiovascular health as a surgeon at the Texas Heart Institute or on health care innovation as the director of the Center for Device Innovation at the Texas Medical Center. However, his role as chief medical officer of BiVACOR might be his most significant contribution to health care yet.

The company's Total Artificial Heart is unlike any cardiovascular device that's existed, Cohn explains on the Houston Innovators Podcast. While most devices are used temporarily for patients awaiting a heart transplant, BiVACOR's TAH has the potential to be a permanent solution for the 200,000 patients who die of heart failure annually. Last year, only around 4,000 patients were able to receive heart transplants.

"Artificial hearts historically have had bladders that ejected and filled 144,000 times a day. They work great for temporary support, but no one is suggesting they are permanent devices," Cohn says on the show.

The difference with BiVACOR's device is it abandons the bladder approach. Cohn explains that as assist pumps evolved — something his colleague, Dr. Bud Frasier, had a huge impact on — they featured new turbine and rotor technology. Daniel Timms, BiVACOR's founder and CTO, iterated on this technology beginning when he was a postdoctoral student at Queensland University of Technology in Australia.

"BiVACOR is the first artificial heart that leverages what we learned from that whole period — it has no bladders, it has no valves. It has one moving part, and that moving part is suspended in an electromagnetic field controlled by a computer and changed thousands of times a second," Cohn says. "It will never wear out, and that's why we think it's the world's first total artificial heart."

The company is seeing momentum, celebrating its first successful human implantation last month. The device was used for eight days on a patient at Baylor St. Luke’s Medical Center before the patient received a heart transplant.

Cohn says that BiVACOR has plans to use the TAH as "bridge-to-transplant" device in several other surgeries and expects to get FDA approval for that purpose in the next three to four years before working toward clearance for total artificial heart transplants.

Cohn has worked to support medical device startups at CDI at TMC for the seven years it has existed — first under Johnson and Johnson and then under TMC when it took the program over. He describes the center and its location as the ideal place for developing the future of health care, with Houston rising up to compete with regions known for medical device success — both coasts and Minnesota.

"Being in the shadow of the largest medical center on the planet — 106,000 employees show up there every 24 hours," Cohn says, "if you want to innovate, this is the place to do it."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston Innovation Awards to honor 2 trailblazers with posthumous recognition

top leaders

Last month, the Houston innovation community suffered the loss of two business leaders who left a significant impact on the ecosystem. In November, both individuals' careers will be recognized with Trailblazer Legacy Awards.

Every year, the Houston Innovation Awards honors a Trailblazer Award recipient for their past and future dedication to startups in Houston, and this year InnovationMap is doing approaching the award differently in light of recent events. Paul Frison, founder of the Houston Technology Center, and Scott Gale, executive director of Halliburton Labs, will receive the award posthumously. Frison died on September 5, and Gale died on September 24. The award was decided on by the 2024 judges and InnovationMap.

“I am immensely proud to honor these two remarkable individuals with the Trailblazer Award this year. It is fitting, as they represent two generations of building Houston’s ecosystem," 2023 Trailblazer Award recipient Brad Burke, managing director of the Rice Alliance and the associate vice president for industry and new ventures within Rice University's Office of Innovation, tells InnovationMap.

"Paul Frison was a pioneering leader who helped establish the Houston Technology Center and fostered the city’s tech ecosystem during the initial technology boom around the year 2000. Scott Gale, through his work at Halliburton Labs over the past five years, has been instrumental in launching Houston’s energy transition ecosystem," he continues. "Both have played pivotal roles in championing technology innovators.”

A long-time Houston businessman, Frison founded HTC in 1999 and served as its CEO and president. The organization evolved into Houston Exponential several years ago. Frison remained active within Houston innovation until 2020. Prior to HTC, he served in various executive roles at American Hospital Supply, LifeMark, ComputerCraft, and LifeCell, spending the last 50 of his years in Houston. Born in Glendale, California, he served in the Unites States Coast Guard.

"Houston's vibrant technology entrepreneurship ecosystem is the product of Paul Frison's commitment to innovation, integrity, and growth for our community," says Walter Ulrich, former president and CEO of HTC. "He is the father of Houston's tech ecosystem, CEO of one of Houston's first tech Unicorns, founder of the Houston Technology Center ranked as a top ten technology incubator by Forbes, philanthropist, veteran, and family man."

Gale helped to launch Halliburton Labs in 2020. Prior to that role, he lead global strategy initiatives for Halliburton. A Brigham Young University graduate, he received his MBA from Rice University in 2019, where he co-founded the Jones Student Association for Executives. After his graduation, he served on the the Rice Business Alumni Association Board and the Energy Advisory Board for the Rice Alliance Clean Energy Accelerator. He was also a voice actor and the co-host of two podcasts: Rice University's Owl Have You Know Podcast, which shares experiences of Rice's business community, and the Curiosity podcast, which explored optimism and curiosity with guests and co-host Brad Rossacci.

"We established the Trailblazer Award to recognize the city's innovation leaders, and Scott and Paul both more than deserve to be recognized for their contributions to Houston," Natalie Harms, editor of InnovationMap, says. "My hope is that this year's Trailblazer Legacy Awards pay tribute to their lasting impacts."

The awards will be presented at the November 14 event.

Rice researchers secure $35M federal grant to advance medical device technology

big money

Rice University has secured part of a nearly $35 million federal grant aimed at commercializing a bioelectric implant for treatment of type 2 diabetes and obesity.

The federal Advanced Research Projects Agency for Health awarded the $34.9 million grant to Rice and several other universities.

Rice’s Biotech Launch Pad will lead the effort to commercialize the self-contained, implantable Rx On-site Generation Using Electronics (ROGUE) device. ROGUE houses cells that are engineered to produce type 2 diabetes and obesity therapies in response to patients’ needs.

Carnegie Mellon University leads the team of researchers handling development and testing of ROGUE, which acts as a “living pharmacy” designed to make biologic drugs available on demand in a patient’s body.

The ROGUE initiative aims to keep the cost of this treatment significantly below the cost of other biologics-based treatments.

“ROGUE’s innovative design combines efficient biological manufacturing, long-term durability, and patient-friendly features that have the potential to transform the landscape of biologics delivery,” Omid Veiseh, professor of bioengineering and faculty director of the Rice Biotech Launch Pad, says in a news release.

Paul Wotton, an in-house entrepreneur at the university and executive director of the Rice accelerator, is helping guide ROGUE toward becoming an independent company.

“With the Biotech Launch Pad, our goal is venture creation in parallel to the groundbreaking research at Rice and its collaborating institutions,” Wotton says.

Omid Veiseh is professor of bioengineering and faculty director of the Rice Biotech Launch Pad. Photo courtesy Rice University